How many institutions held ACRS - Aclaris Therapeutics, Inc. - Common Stock, $0.00001 par value in Q2 2017?

101 institutional investors reported ACRS - Aclaris Therapeutics, Inc. - Common Stock, $0.00001 par value for Q2 2017. Use the holders table for investor-level position and value details.

Aclaris Therapeutics, Inc. - Common Stock, $0.00001 par value (ACRS)

Q: What does CUSIP 00461U105 represent in this 13F holders report?

CUSIP 00461U105 is the security identifier for ACRS - Aclaris Therapeutics, Inc. - Common Stock, $0.00001 par value used to aggregate holder disclosures.

CUSIP: 00461U105

Q2 2017 13F Holders as of 30 Jun 2017

Type / Class: Equity / Common Stock, $0.00001 par value
Shares outstanding: 140,909,091
Total 13F shares: 25,609,895
Share change: +1,898,817
Total reported value: $694,432,125
Price per share: $27.12
Number of holders: 101
Value change: +$43,716,393
Number of buys: 72
Number of sells: 48

Quarterly Holders Quick Answers

What is CUSIP 00461U105?
CUSIP 00461U105 identifies ACRS - Aclaris Therapeutics, Inc. - Common Stock, $0.00001 par value in SEC institutional holdings data.

Need full ownership history?
Open the full security ownership history page.

Next holder-history checks

These links keep the next click tied to holder verification, nearby quarters, or outside-13F ownership context.

Back to full security ownership history for the broader multi-quarter picture.
Latest 13F filings for newly reported positions across managers.
Latest Schedule 13D/13G reports for ownership changes outside the 13F cadence.
SEC investors directory for manager drilldown.

Explore More Reporting Periods

Jump to adjacent filing periods for faster comparison and easier crawl discovery.

Newer quarter: Q3 2017
Previous quarter: Q1 2017

Recent filing periods for CUSIP 00461U105:

Q1 2026 Q4 2025 Q3 2025 Q2 2025 Q1 2025 Q4 2024 Q3 2024 Q2 2024

Top shareholders of ACRS - Aclaris Therapeutics, Inc. - Common Stock, $0.00001 par value (13F + 13D/G + 3/4/5)

Grouped by holder across the latest SEC ownership disclosures. Ownership % is shown only when it is directly reported or safely comparable across share classes.

Methodology: rows are grouped by holder and ranked by the holder's primary source value. — indicates unavailable or non-comparable values; "mixed-class rows" means the latest filing spans non-comparable classes.

Holder	Source	Role / Reporting	Ownership %	Shares	Holdings Value	12M Net Δ	As of	Details
Vivo Capital, LLC	13F	Company	2%	2,858,569	$85,243,000	—	31 Mar 2017	13F
FMR LLC	13F	Company	1.2%	1,653,937	$49,321,000	—	31 Mar 2017	13F
Sofinnova Management VIII, L.L.C.	13F	Company	1.1%	1,539,480	$45,907,000	—	31 Mar 2017	13F
PERCEPTIVE ADVISORS LLC	13F	Company	0.89%	1,260,847	$37,598,000	—	31 Mar 2017	13F
FRANKLIN RESOURCES INC	13F	Company	0.89%	1,258,277	$37,522,000	—	31 Mar 2017	13F
PointState Capital LP	13F	Company	0.69%	971,100	$28,958,000	—	31 Mar 2017	13F
Polar Capital LLP	13F	Company	0.69%	971,049	$28,957,000	—	31 Mar 2017	13F
Cormorant Asset Management, LP	13F	Company	0.57%	800,000	$23,856,000	—	31 Mar 2017	13F
BlackRock Finance, Inc.	13F	Company	0.55%	781,043	$23,291,000	—	31 Mar 2017	13F
VANGUARD GROUP INC	13F	Company	0.5%	711,519	$21,218,000	—	31 Mar 2017	13F
Marshall Wace North America L.P.	13F	Company	0.5%	703,861	$21,116,000	—	31 Mar 2017	13F
WESTFIELD CAPITAL MANAGEMENT CO LP	13F	Company	0.49%	695,502	$20,740,000	—	31 Mar 2017	13F
Rock Springs Capital Management LP	13F	Company	0.48%	675,000	$20,129,000	—	31 Mar 2017	13F
EcoR1 Capital, LLC	13F	Company	0.48%	673,100	$20,072,000	—	31 Mar 2017	13F
Invesco Ltd.	13F	Company	0.46%	654,976	$19,531,000	—	31 Mar 2017	13F
Point72 Asset Management, L.P.	13F	Company	0.33%	459,916	$13,715,000	—	31 Mar 2017	13F
ADAGE CAPITAL PARTNERS GP, L.L.C.	13F	Company	0.32%	450,000	$13,419,000	—	31 Mar 2017	13F
LOOMIS SAYLES & CO L P	13F	Company	0.28%	399,963	$11,927,000	—	31 Mar 2017	13F
BALYASNY ASSET MANAGEMENT L.P.	13F	Company	0.28%	398,750	$11,891,000	—	31 Mar 2017	13F
DEERFIELD MANAGEMENT COMPANY, L.P.	13F	Company	0.27%	375,000	$11,183,000	—	31 Mar 2017	13F
EAGLE ASSET MANAGEMENT INC	13F	Company	0.25%	350,630	$10,455,000	—	31 Mar 2017	13F
PRICE T ROWE ASSOCIATES INC /MD/	13F	Company	0.24%	344,317	$10,268,000	—	31 Mar 2017	13F
DRIEHAUS CAPITAL MANAGEMENT LLC	13F	Company	0.24%	331,197	$9,876,000	—	31 Mar 2017	13F
ACUTA CAPITAL PARTNERS, LLC	13F	Company	0.14%	200,000	$5,964,000	—	31 Mar 2017	13F
STATE STREET CORP	13F	Company	0.14%	197,889	$5,902,000	—	31 Mar 2017	13F
FIL Ltd	13F	Company	0.14%	195,692	$5,835,000	—	31 Mar 2017	13F
Alyeska Investment Group, L.P.	13F	Company	0.14%	192,957	$5,754,000	—	31 Mar 2017	13F
COLUMBUS CIRCLE INVESTORS	13F	Company	0.13%	180,320	$5,377,000	—	31 Mar 2017	13F
TIAA CREF INVESTMENT MANAGEMENT LLC	13F	Company	0.13%	178,274	$5,316,000	—	31 Mar 2017	13F
NORTHERN TRUST CORP	13F	Company	0.12%	168,488	$5,024,000	—	31 Mar 2017	13F
HighTower Advisors, LLC	13F	Company	0.1%	143,891	$4,291,000	—	31 Mar 2017	13F
PUTNAM INVESTMENTS LLC	13F	Company	0.1%	140,268	$4,183,000	—	31 Mar 2017	13F
EVENTIDE ASSET MANAGEMENT, LLC	13F	Company	0.1%	140,000	$4,175,000	—	31 Mar 2017	13F
Foresite Capital Management III, LLC	13F	Company	0.1%	140,000	$4,175,000	—	31 Mar 2017	13F
Informed Momentum Co LLC	13F	Company	0.09%	129,066	$3,849,000	—	31 Mar 2017	13F
Folger Hill Asset Management LP	13F	Company	0.09%	124,299	$3,707,000	—	31 Mar 2017	13F
GEODE CAPITAL MANAGEMENT, LLC	13F	Company	0.08%	118,036	$3,519,000	—	31 Mar 2017	13F
NEXTHERA CAPITAL LP	13F	Company	0.08%	111,500	$3,325,000	—	31 Mar 2017	13F
FARALLON CAPITAL MANAGEMENT LLC	13F	Company	0.08%	106,894	$3,188,000	—	31 Mar 2017	13F
Redmile Group, LLC	13F	Company	0.06%	90,700	$2,705,000	—	31 Mar 2017	13F
DEUTSCHE BANK AG\	13F	Company	0.06%	90,161	$2,687,000	—	31 Mar 2017	13F
Bank of New York Mellon Corp	13F	Company	0.06%	88,184	$2,630,000	—	31 Mar 2017	13F
RENAISSANCE TECHNOLOGIES LLC	13F	Company	0.06%	88,079	$2,627,000	—	31 Mar 2017	13F
C WorldWide Group Holding A/S	13F	Company	0.06%	81,500	$2,430,000	—	31 Mar 2017	13F
Iguana Healthcare Management, LLC	13F	Company	0.05%	75,000	$2,237,000	—	31 Mar 2017	13F
AXIOM INVESTORS LLC /DE	13F	Company	0.05%	67,467	$2,012,000	—	31 Mar 2017	13F
Granite Point Capital Management, L.P.	13F	Company	0.05%	65,680	$1,959,000	—	31 Mar 2017	13F
Jefferies Group LLC	13F	Company	0.05%	63,908	$1,906,000	—	31 Mar 2017	13F
MOORE CAPITAL MANAGEMENT, LP	13F	Company	0.04%	62,500	$1,864,000	—	31 Mar 2017	13F
PARAMETRIC PORTFOLIO ASSOCIATES LLC	13F	Company	0.04%	55,397	$1,652,000	—	31 Mar 2017	13F

Institutional Holders of Aclaris Therapeutics, Inc. - Common Stock, $0.00001 par value (ACRS) as of Q2 2017

As of 30 Jun 2017, Aclaris Therapeutics, Inc. - Common Stock, $0.00001 par value (ACRS) was held by 101 institutional shareholders that filed Form 13F with the SEC. Together, they reported ownership of 25,609,895 shares. The largest 10 holders included Vivo Capital, LLC, FRANKLIN RESOURCES INC, FMR LLC, Sofinnova Management VIII, L.L.C., EAGLE ASSET MANAGEMENT INC, Polar Capital LLP, WESTFIELD CAPITAL MANAGEMENT CO LP, BlackRock Inc., Marshall Wace North America L.P., and Point72 Asset Management, L.P.. This page lists 101 institutional shareholders reporting positions in this security for the Q2 2017 filing period.

Investor	Option	Weight %	Change %	Value $	* Price	Shares	Share Change	Activity	Report Period

Compare Q2 2017 vs Q1 2017 Across Filers

Q1 2017 holders

111

Q2 2017 holders

101

Holder diff

-10

Investor	Q1 2017 Shares	Q2 2017 Shares	Share Diff	Share Chg %	Q1 2017 Value $	Q2 2017 Value $	Value Diff $	Value Chg %

Trend: ostatnie 8 kwartałów (+ wybrane okresy porównania).

Quarterly Holders Trend

Quarterly Value Trend

Quarterly Shares Trend

* Reported Price is the price of the security as of the portfolio date. This value is significant in that it is the last known price at which the security was still held.
An asterisk sign (*) next to the price indicates that the price is likely invalid.